Ciraparantag TFA
Modify Date: 2025-08-26 23:26:59
Ciraparantag TFA structure
|
Common Name | Ciraparantag TFA | ||
|---|---|---|---|---|
| CAS Number | 1438492-27-3 | Molecular Weight | 740.74 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H50F6N12O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Ciraparantag TFACiraparantag TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban[1][2][3][4]. |
| Name | Ciraparantag TFA |
|---|
| Description | Ciraparantag TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban[1][2][3][4]. |
|---|---|
| Related Catalog | |
| Target |
thrombin, factor Xa[1] |
| In Vitro | Ciraparantag TFA is a small-molecule antidote for unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and certain direct oral anticoagulants (DOACs)[2]. Ciraparantag TFA is a small synthetic and cationic molecule that binds direct Xa inhibitors, direct thrombin inhibitors, and unfractionated and low molecular weight heparin (LMWH) through non-covalent hydrogen bonds and charge–charge interactions[3]. |
| References |
| Molecular Formula | C26H50F6N12O6 |
|---|---|
| Molecular Weight | 740.74 |
| InChIKey | FEGHGRKJVFCLFT-MPGISEFESA-N |
| SMILES | NC(N)=NCCCC(N)C(=O)NCCCN1CCN(CCCNC(=O)C(N)CCCN=C(N)N)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F |